| Identification | Back Directory | [Name]
beta-d-Glucan, (1->3),(1->6)- | [CAS]
53238-80-5 | [Synonyms]
S 4001
Antivir
Imuneks
Immutol
Glucanil
Glucan P
Agrastim
Gluimmun
Aqua-beta
Macrogard
Leucogard
Glucaferm
Glucoprime
Betaglucin
Betagard A
Imunoglukan
Imprime PGG
Leiber Beta-S
HA-beta-Glucan
MacroForce plus IP 6
BETA-GLUCAN, β-GLUCAN
Fermented Beta-Glucan LQ
beta-(1-3),(1-6)-D-Glucan
beta-d-Glucan, (1->3),(1->6)- | [EINECS(EC#)]
258-443-2 | [MDL Number]
MFCD03001549 |
| Hazard Information | Back Directory | [Uses]
Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response[1][2]. | [in vivo]
Odetiglucan (1.2 mg, i.v., once a week, 3 weeks) inhibits the proliferation of cancer cells and triggers an effective T cell-mediated response against liver metastases in a mouse model of pancreatic cancer[1]. | Animal Model: | Pancreatic Ductal Adenocarcinoma (PDAC) mouse model[1] | | Dosage: | 1.2 mg; once a week; 3 weeks | | Administration: | Intravenous injection (i.v.) | | Result: | Activated liver-resident macrophages, inhibited cancer cell proliferation, and drived T cell activation and macrophage repolarization in mouse liver metastases. |
| [References]
[1] Stacy K Thomas, et al. Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nat Commun. 2023 Oct 10;14(1):6330. DOI:10.1038/s41467-023-41771-z
[2] WHO Drug Information. International Nonproprietary Names for Pharmaceutical |
|
|